Contracts › HT942525CE039
HT942525CE039: A Phase 1 Placebo-Controlled Dose-Escalation Safety and Pharmacokinetic Study of In-007, a Nebulized, Pan-Sars ACE2-DECOY Therapeutic for Pandemic Preparedness
Awarded to Inhalon Biopharma, Inc. by Defense Health Agency.
$3.2Mobligated
$3.2Mpotential value
31 December 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | HT942525CE039 |
|---|---|
| Awardee | Inhalon Biopharma, Inc. |
| Awarding agency | Defense Health Agency |
| Awarding office | ARMY MED RES ACQ ACTIVITY |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN13 Health R&D Services; Health Care Services; Experimental Development |
| Place of performance | NC |
| Offers received | 44 |
| Period of performance | 22 September 2025 to 31 December 2027 |
| Potential end | 31 December 2027 |
| Estimated recompete solicitation | ~Q3 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record